Orexigen cuts 40% of staff in wake of uncertainty from further FDA demands on Contrave
This article was originally published in Scrip
Executive Summary
Orexigen Therapeutics has reported that it is laying off 23 staffers, or about 40% of its work force, as it figures out how it will move forward.